The objective ofthe Glioma SPORE Developmental Research Program (DRP) is to identify innovative pilot research projects in glioblastoma that have translational potential. The DRP will establish a solicitation and review process to select meritorious pilot projects for funding. The solicitation process will capitalize on an established, extensive Dana-Farber/Harvard Cancer Center (DF/HCC) communications Infrastructure to widely disseminate an annual Request for Proposals (RFP). The review process will utilize an experienced panel of DF/HCC glioma scientists. The DRP will provide limited-duration funding for innovative projects that have ultimate translational potential and could synergize with existing SPORE projects and cores. The DRP applications will also be judged for their potential to emerge as full projects in future years of the SPORE program. The DRP will employ a monitoring process to measure progress and outcomes of DRP projects including the possible elevation of successful DRP awards to full projects. The program will be closely monitored through clearly established metrics and oversight by the DRP Awards Committee. DRP awardees will be required to present progress reports at the annual SPORE retreat attended by the SPORE Internal and External Advisory Boards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA165962-01A1
Application #
8588505
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-19
Project End
2018-07-31
Budget Start
2013-09-19
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$58,623
Indirect Cost
$15,459
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Taylor, Jennie W; Dietrich, Jorg; Gerstner, Elizabeth R et al. (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol 121:557-63
Schmit, Fabienne; Utermark, Tamara; Zhang, Sen et al. (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111:6395-400
Cheng, Hailing; Liu, Pixu; Zhang, Fan et al. (2014) A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 74:15-23
Francis, Joshua M; Zhang, Cheng-Zhong; Maire, Cecile L et al. (2014) EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 4:956-71
Sullivan, James P; Nahed, Brian V; Madden, Marissa W et al. (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299-309
Maire, Cecile L; Ligon, Keith L (2014) Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 16 Suppl 8:viii1-6
Wakimoto, Hiroaki; Tanaka, Shota; Curry, William T et al. (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20:2898-909